August 13, 2019 Novartis cast-off gives Pharming a gap-filler Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
October 12, 2018 Cost-effectiveness doubts could hit Shire’s Takhzyro launch A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.
September 19, 2018 The other shoe drops for Pharming A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
August 09, 2018 Shire dodges pricing questions as lanadelumab’s big day nears Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?